The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Logran     sodium 2-(imidazol-1-ylmethyl)-4,5...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Imitrodast


High impact information on Imitrodast

  • The thromboxane A2 synthetase inhibitors OKY-046 (10(-5) mol/l) and RS-5186 (10(-5) mol/l) did not attenuate the contractions either with or without endothelium [3].
  • This study was designed to determine the effect of sodium 6-(2-[1-(1H)-imidazolyl]methyl-4,5-dihydrobenzo[b] thiophene)carboxylate (RS-5186), a new thromboxane A2 (TXA2) synthetase inhibitor, on mitochondrial function and lysosomal integrity in ischemic myocardium [4].

Analytical, diagnostic and therapeutic context of Imitrodast

  • The remaining six dogs without administration of RS-5186 were used as a control group [1].
  • In contrast, in the RS-5186 treated group (2 mg/kg i.v.), both infarct size and MPO activity did not increase with prolongation of the reperfusion period (infarct size: 12.8 +/- 5.5 to 10.3 +/- 3.6%; MPO activity: 318.8 +/- 36.7 to 381.2 +/- 72.6 units/g wet weight) [5].


  1. Effects of thromboxane synthetase inhibitor (RS-5186) on experimentally-induced cerebral vasospasm. Takeuchi, H., Tanabe, M., Okamoto, H., Yamazaki, M. Neurol. Res. (1999) [Pubmed]
  2. RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. Ushiyama, S., Ito, T., Asai, F., Oshima, T., Terada, A., Matsuda, K., Yamazaki, M. Thromb. Res. (1988) [Pubmed]
  3. Prostaglandin H2 as an endothelium-derived contracting factor modulates endothelin-1-induced contraction. Asano, H., Shimizu, K., Muramatsu, M., Iwama, Y., Toki, Y., Miyazaki, Y., Okumura, K., Hashimoto, H., Ito, T. J. Hypertens. (1994) [Pubmed]
  4. Effect of a novel thromboxane A2 synthetase inhibitor on ischemia-induced mitochondrial dysfunction in canine hearts. Ogawa, T., Hieda, N., Sugiyama, S., Toki, Y., Ito, T., Ogawa, K., Satake, T., Ozawa, T. Arzneimittel-Forschung. (1988) [Pubmed]
  5. Reduction of infarct size and infiltration of polymorphonuclear leukocytes by a thromboxane synthetase inhibitor. Studies in a rabbit ischemic heart model. Ito, T., Asai, F., Ushiyama, S., Matsuda, K., Oshima, T. Arzneimittel-Forschung. (1990) [Pubmed]
WikiGenes - Universities